{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-000205","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.106777+00:00","generated_at":"2026-06-27T19:43:31.499273+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sarepta: $612M FY2021 revenue; SRP-9001 gene therapy shows significant functional improvement in DMD study","bullets":["Preliminary FY2021 revenue $612M, Q4 revenue $178.7M from DMD therapies; cash $2.1B at year-end.","SRP-9001 (delandistrogene moxeparvovec): Part 2 of Study 102 met primary endpoint with NSAA improvement vs external control (p=0.0009).","No new safety signals; no treatment-related SAEs, deaths, or discontinuations in Part 2.","Company reaffirms confidence in EMBARK phase 3 global study, currently dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-000205","json":"https://secwatch.observer/filing/0000950170-22-000205.json","markdown":"https://secwatch.observer/filing/0000950170-22-000205.md","text":"https://secwatch.observer/filing/0000950170-22-000205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000095017022000205/0000950170-22-000205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000095017022000205/srpt-20220110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:43:31.499273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}